Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

• Status: Completed
• Trial end date: 2015-02-01

Summary

The main purpose of this study is to assess the optimum dose of the following medications when they are given together:

• BIBW 2992 and paclitaxel (Taxol)

• BIBW 2992 and paclitaxel and bevacizumab (Avastin)

• BIBW 2992 and carboplatin

• BIBW 2992 and paclitaxel and carboplatin The effect of the different drug combinations will also be assessed.

• Phase: Phase 1

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Afatinib; Albumin-Bound Paclitaxel; Bevacizumab; Carboplatin; Paclitaxel